Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.1 USD | +2.31% | -2.82% | +11.91% |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | 44.27M | Capitalization | 109M |
---|---|---|---|---|---|
Net income 2024 * | -49M | Net income 2025 * | -22M | EV / Sales 2024 * | - |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 2.45 x |
P/E ratio 2024 * |
-1.86
x | P/E ratio 2025 * |
-5.25
x | Employees | 20 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 88.18% |
Latest transcript on Cellectar Biosciences, Inc.
1 day | +2.31% | ||
1 week | -2.82% | ||
Current month | -22.11% | ||
1 month | -20.92% | ||
3 months | -26.37% | ||
6 months | +29.17% | ||
Current year | +11.91% |
Managers | Title | Age | Since |
---|---|---|---|
James V. Caruso
CEO | Chief Executive Officer | 65 | 15-06-14 |
Chad J. Kolean
DFI | Director of Finance/CFO | 59 | 14-05-27 |
Andrei Shustov
CTO | Chief Tech/Sci/R&D Officer | - | 23-02-14 |
Members of the board | Title | Age | Since |
---|---|---|---|
Fred Driscoll
BRD | Director/Board Member | 74 | 17-04-06 |
Douglas Swirsky
CHM | Chairman | 54 | 17-04-06 |
John Neis
BRD | Director/Board Member | 68 | 08-01-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-29 | 3.1 | +2.31% | 715 776 |
24-04-26 | 3.03 | +0.33% | 686,677 |
24-04-25 | 3.02 | -1.31% | 690,802 |
24-04-24 | 3.06 | -1.61% | 1,043,212 |
24-04-23 | 3.11 | -2.51% | 899,197 |
Delayed Quote Nasdaq, April 29, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+11.91% | 109M | |
+26.47% | 661B | |
+26.74% | 566B | |
-6.33% | 352B | |
+19.35% | 332B | |
+4.23% | 283B | |
+13.43% | 231B | |
+4.71% | 200B | |
-9.53% | 195B | |
-4.04% | 145B |
- Stock Market
- Equities
- CLRB Stock